Discontinued — last reported Q4 '25
Parker-Hannifin Business Sale Proceeds decreased by 41.2% to $303.00K in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 85.6%, from $2.11M to $303.00K.
An increase signals portfolio optimization or a strategic pivot, while a lack of proceeds suggests a stable, long-term asset base.
This metric represents the cash inflows received from the divestiture or sale of business segments, product lines, or su...
Occurs sporadically; peers often divest legacy segments to focus on high-margin innovation areas like continuous glucose monitoring or diagnostics.
cf_proceeds_from_sale_of_business| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $2.47M | $900.00K | $0.00 | $441.34M | $5.96M | $24.42M | $1.49M | $36.69M | $37.90M | $966.00K | $2.11M | $884.00K | $621.30M | $515.00K | $303.00K |
| QoQ Change | — | — | — | -63.5% | -100.0% | — | -98.6% | +309.7% | -93.9% | >999% | +3.3% | -97.5% | +117.9% | -58.0% | >999% | -99.9% | -41.2% |
| YoY Change | — | — | — | — | — | — | +141.7% | >999% | — | -91.7% | +536.0% | -96.0% | +41.6% | -97.6% | >999% | -46.7% | -85.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.